Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Winthrop

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
RMD Open|November 14, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature researchAndreas Kerschbaumer, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases|February 11, 2025
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases - a systematic literature review informing the 2024 update of an international expert consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
Neurology and Therapy|March 14, 2022
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with OfatumumabAnne H Cross, Silvia Delgado, Mario Habek, et al.
The Lancet. Respiratory Medicine|September 13, 2024
Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 monthsCharles S Haworth, Michal Shteinberg, Kevin Winthrop, et al.
The Lancet. Infectious Diseases|January 29, 2022
Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseasesChristoph Lange, Erik C Böttger, Emmanuelle Cambau, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 30, 2020
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1Ted R Mikuls, Sindhu R Johnson, Liana Fraenkel, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 5, 2020
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3Ted R Mikuls, Sindhu R Johnson, Liana Fraenkel, et al.
RMD Open|October 19, 2022
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseasesKastriot Kastrati, Daniel Aletaha, Gerd R Burmester, et al.
Modern Rheumatology|April 2, 2022
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 yearsNaoki Ishiguro, Yoshiya Tanaka, Tsukasa Matsubara, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 1, 2020
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2Ted R Mikuls, Sindhu R Johnson, Liana Fraenkel, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
RMD Open|November 14, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature researchAndreas Kerschbaumer, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases|February 11, 2025
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases - a systematic literature review informing the 2024 update of an international expert consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
Neurology and Therapy|March 14, 2022
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with OfatumumabAnne H Cross, Silvia Delgado, Mario Habek, et al.
The Lancet. Respiratory Medicine|September 13, 2024
Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 monthsCharles S Haworth, Michal Shteinberg, Kevin Winthrop, et al.
The Lancet. Infectious Diseases|January 29, 2022
Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseasesChristoph Lange, Erik C Böttger, Emmanuelle Cambau, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 30, 2020
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1Ted R Mikuls, Sindhu R Johnson, Liana Fraenkel, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 5, 2020
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3Ted R Mikuls, Sindhu R Johnson, Liana Fraenkel, et al.
RMD Open|October 19, 2022
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseasesKastriot Kastrati, Daniel Aletaha, Gerd R Burmester, et al.
Modern Rheumatology|April 2, 2022
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 yearsNaoki Ishiguro, Yoshiya Tanaka, Tsukasa Matsubara, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 1, 2020
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2Ted R Mikuls, Sindhu R Johnson, Liana Fraenkel, et al.
Pageof 8